Current portfolio

Hutchmed

Among the first global-focused novel drug discovery companies in China

HUTCHMED is an innovative, commercial-stage biopharmaceutical company committed to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.

  • Sektor
    Healthcare
  • Land
    Greater China
  • Fond
    The Baring Asia Private Equity Fund VII
  • Entry
    2021
  • Web
Logo

Prenumerera

Prenumerera på EQT:s press releaser, regulatoriska press releaser och updates.

Typ av nyheter
Preferred language
EQT logo
© EQT AB 2022. EQT AB (PUBL). REGISTRATED OFFICE IN STOCKHOLM, SWEDEN. REGISTRATION NUMBER: 556849-4180